<mets:mets xmlns:mets="http://www.loc.gov/METS/" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xlink="http://www.w3.org/1999/xlink">
    <mets:dmdSec ID="DMD_31fec3ee-a5fb-4d6f-9d2d-eb17be46df7c">
        <mets:mdWrap MIMETYPE="text/xml" MDTYPE="MODS">
            <mets:xmlData>
                <mods xmlns="http://www.loc.gov/mods/v3" version="3.7" xmlns:vl="http://visuallibrary.net/vl">
                    <titleInfo lang="eng">
                        <title>Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?</title>
                    </titleInfo>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/143607693">
                        <displayForm>Lenders, Malte</displayForm>
                        <namePart type="given">Malte</namePart>
                        <namePart type="family">Lenders</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/143713094">
                        <displayForm>Schmitz, Boris</displayForm>
                        <namePart type="given">Boris</namePart>
                        <namePart type="family">Schmitz</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1027044093">
                        <displayForm>Brand, Stefan-Martin</displayForm>
                        <namePart type="given">Stefan-Martin</namePart>
                        <namePart type="family">Brand</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1070692077">
                        <displayForm>Brand, Eva</displayForm>
                        <namePart type="given">Eva</namePart>
                        <namePart type="family">Brand</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <typeOfResource>text</typeOfResource>
                    <genre authority="dini">article</genre>
                    <originInfo>
                        <dateIssued encoding="w3cdtf" keyDate="yes">2018-09-29</dateIssued>
                        <dateIssued encoding="w3cdtf">2019-07-25</dateIssued>
                    </originInfo>
                    <language>
                        <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
                    </language>
                    <abstract lang="eng">Fabry disease (FD) is a rare X-linked disorder caused by a deficiency of lysosomal α-galactosidase A activity. Treatment with recombinant enzyme replacement therapy is available since 2001 and the effects of anti-drug antibodies (ADA) on therapy efficacy and disease outcome in affected patients have been controversially reported. In this letter we discuss the importance of adequate measurements of neutralizing ADAs and appropriate longitudinal analysis to determine therapy efficiency and clinical outcome in patients with FD.</abstract>
                    <note type="citation/reference">Orphanet Journal of Rare Diseases 13 (2018 ) 171, 1-2</note>
                    <note>Finanziert durch den Open-Access-Publikationsfonds 2018 der Deutschen Forschungsgemeinschaft (DFG) und der Westfälischen Wilhelms-Universität Münster (WWU Münster).</note>
                    <subject lang="eng">
                        <topic>Enzyme replacement therapy</topic>
                        <topic>Longitudinal</topic>
                        <topic>Prospective</topic>
                    </subject>
                    <classification authority="ddc">610</classification>
                    <identifier type="urn">urn:nbn:de:hbz:6-84129538247</identifier>
                    <identifier type="doi">10.1186/s13023-018-0916-1</identifier>
                    <accessCondition type="use and reproduction" xlink:href="http://creativecommons.org/licenses/by/4.0/">CC BY 4.0</accessCondition>
                    <recordInfo>
                        <recordIdentifier>muenster_miami_31fec3ee-a5fb-4d6f-9d2d-eb17be46df7c</recordIdentifier>
                    </recordInfo>
                    <extension>
                        <vl:doctype>oaArticle</vl:doctype>
                    </extension>
                </mods>
            </mets:xmlData>
        </mets:mdWrap>
    </mets:dmdSec>
    <mets:fileSec>
        <mets:fileGrp USE="pdf upload">
            <mets:file MIMETYPE="application/pdf" ID="FILE_31fec3ee-a5fb-4d6f-9d2d-eb17be46df7c_1">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/document/miami/31fec3ee-a5fb-4d6f-9d2d-eb17be46df7c/artikel_lenders_2018.pdf" LOCTYPE="URL"/>
            </mets:file>
        </mets:fileGrp>
    </mets:fileSec>
    <mets:structMap TYPE="LOGICAL">
        <mets:div TYPE="document" ID="muenster_miami_31fec3ee-a5fb-4d6f-9d2d-eb17be46df7c" DMDID="DMD_31fec3ee-a5fb-4d6f-9d2d-eb17be46df7c">
            <mets:fptr FILEID="FILE_31fec3ee-a5fb-4d6f-9d2d-eb17be46df7c_1"/>
        </mets:div>
    </mets:structMap>
</mets:mets>
